Evidence status: each field shows source quality, applicability, and review date. Research pending, information not established in reviewed sources, and vendor documentation pending are distinct outcomes.
Clinical fit
What this tool is for
Start with the authorized purpose, then verify how it fits your service line and reading workflow.
Exact purpose
Notification-only triage of suspected intracranial hemorrhage on non-contrast head CT
FDA source Exact FDA submission Checked 2026-09-05
Case-level suspected-ICH notification and non-diagnostic compressed image preview in a mobile app; no marking, highlighting or segmentation on the original image.
FDA source Exact FDA submission Checked 2026-09-05
Notifications are not diagnostic. Users must review non-compressed images on a diagnostic viewer and perform full clinical assessment; cases are not removed or deprioritized in the standard worklist.
FDA source Exact FDA submission Checked 2026-09-05
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
FDA submission
K243363
FDA source Exact FDA submission Checked 2026-08-31
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version.
Evidence summary
Standalone retrospective study of 376 US NCCTs (188 ICH-positive, 188 negative) with two ABR-certified neuroradiologists and third-reader consensus. Test data were newly acquired and independent of development data.
FDA source Exact FDA submission Checked 2026-09-05
K243363 standalone ICH notification performance study
Retrospective standalone performance with independent test data and neuroradiologist consensus reference · 376 US NCCT scans; 188 ICH positive and 188 negative
exact submission · Tested version: JLK-ICH in K243363 · n=376 · Independence not established
Deep learning-assisted detection of intracranial hemorrhage: validation and impact on reader performance
Retrospective reader-performance validation · 1,370 NCCT examinations at one tertiary Korean hospital
product family · Tested version: JLK-ICH; exact K243363 version not established · n=1370 · 1 site · Sponsor or vendor study
PMID:40116947 · doi:10.1007/s00234-025-03560-x
Publication identifies company-employed authors. It is family contextual evidence, not an independent replication or a substitute for FDA study results.
These are common procurement questions; unknown values remain visible until a source supports them.
Pricing and total cost
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-09-06
No primary-source US commercial price reviewed.
Reimbursement and coding
Research pending
Needs research Exact FDA submission Checked 2026-09-06
No applicable payer policy reviewed; overseas procurement mentions do not establish US coverage.
Safety and lifecycle
Postmarket record
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Buyer worksheet
Open questions to take to the vendor
Verify care setting and population: Confirm the intended care setting, patient population, and service line.
Verify security and privacy controls: No current scoped security or mobile-device attestation reviewed.
Verify training: Mobile-app notification response training and local escalation protocol remain unestablished.
Verify pricing and total cost: No primary-source US commercial price reviewed.
Verify reimbursement and coding relevance: No applicable payer policy reviewed; overseas procurement mentions do not establish US coverage.
Verify local validation and lifecycle monitoring: Local notification latency, false-alert and missed-alert monitoring commitments require confirmation.
Verify recalls and postmarket safety signals: No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-06Last searched
22Fields reviewed
11Source classes checked
1Reviewed PubMed leads
0Reviewed trial leads
0Unreviewed FDA recall leads
Stored PubMed candidate and publication metadata/full-text record reviewed; it names JLK-ICH but has company-employed authors and unestablished exact version, so retained only as non-independent product-family context. Stored trial array is empty. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, literature index, peer reviewed publication, trial registry, recall database, pubmed, clinical trials, openfda device recall
HALO analyzes contrast-enhanced brain CTA in the acute setting for suspected anterior-circulation large-vessel occlusion and provides notification support for emergency stroke...
CINA analyzes nonenhanced head CT for suspected intracranial hemorrhage and head CTA for suspected large-vessel occlusion for computer-aided triage and notification in parallel...
BriefCase provides computer-assisted triage and notification for suspected intracranial hemorrhage on noncontrast head CT and or large-vessel occlusion on head CTA in parallel...
Annalise Enterprise prioritizes and notifies trained CT clinicians of suspected acute infarct on non-contrast brain CT for adults; it is a study-level, non-localizing worklist aid...